<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>878</ReferenceId>
        <DateLastUpdated>2018-10-16-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10531220</PubmedId>
            <Abstract>A monoclonal antibody (MAb) was raised against Shiga toxin 2 (Stx2) of Escherichia coli O157:H7. MAb VTm1.1 belonged to the immunoglobulin G1 subclass and had a kappa light chain, and it could neutralize the cytotoxic activity of Stx2 and variants derived from patient strains but not that of variants derived from animals. MAb VTm1.1 was shown to bind to the B subunit of these neutralized Stx2s by Western blotting. Comparison of B-subunit amino acid sequences and reactivities to these Stxs suggested six amino acids (Ser30, Ser53, Glu56, Gln65, Asn68, and Asp69) that were candidates for the MAb VTm1.1 epitope. Consequently, five Stx2 mutants (S30N, S53N, E56H, Q65K, and N68Ter) were prepared by site-directed mutagenesis to determine which residue is essential for the epitope. All of these mutants showed cytotoxicity almost equal to that of the wild-type Stx2. Of the five Stx2 mutants, only E56H could not be neutralized by MAb VTm1.1. Western blot analysis also showed that MAb VTm1.1 could not bind to the E56H B subunit. These results indicated that Glu56 is an important residue recognized by MAb VTm1. 1. Immunofluorescence analysis further indicated that MAb VTm1.1 inhibits the binding of Stx2 to its receptors. MAb VTm1.1 could be a useful therapeutic agent for Shiga toxin-producing E. coli infection.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>5717-22</ArticlePages>
            <ArticleTitle>Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Nakao</LastName>
                    <ForeName>H</ForeName>
                </Author>
                <Author>
                    <LastName>Kiyokawa</LastName>
                    <ForeName>N</ForeName>
                </Author>
                <Author>
                    <LastName>Fujimoto</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Yamasaki</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Takeda</LastName>
                    <ForeName>T</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Infectious Diseases Research, National Children's Medical Research Center, Tokyo 154-8509, Japan.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Bacterial Toxins;Cytotoxins;Epitopes;Shiga Toxins;Trihexosylceramides;globotriaosylceramide</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Monoclonal(immunology); Bacterial Toxins(immunology; metabolism; toxicity); Cytotoxins(immunology); Epitopes; Escherichia coli(pathogenicity); Humans; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Mutagenesis, Site-Directed; Shiga Toxins; Trihexosylceramides(metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>67</Volume>
                <Issue>11</Issue>
                <Title>Infection and immunity</Title>
                <Issn>0019-9567</Issn>
                <MedlineTa>Infect Immun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Mab VTm1.1 - Stx 2</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>E76</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>WP_115443648.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>562</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Abstract</LocationOfData>
                <EpitopeId>779882</EpitopeId>
                <ReferenceRegion>E56</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <EpitopeComments>The enterobacteria phage is the source of the toxin expressed in  E.coli strains such as O157:H7.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 1 and 3</LocationOfData>
                        <BCellId>9993</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>WP_115443648.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>562</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Shiga 2 toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was produced by hybridoma cell line obtained from the fusion of P3U1 mouse myeloma cells (5x3 10&lt;sup&gt;6&lt;/sup&gt; cells) with spleen cells from BALB/c mice immunized with Stx2 toxoid.  Toxoid used for immunizations was produced by formaldehyde treatment of purified Stx2.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>By testing variants and point mutants of Stx2, it was determined that the glutamic acid at position 56 is critical for the binding of monoclonal antibody to the Stx2 protein.  The monoclonal antibody cross-reacted with Stx2 from  various strains of E. coli, including 0157 V50, 0157V354, V601, H7 TK051, 019:H22K080, 022H-KY019, and OUT:H21 TK096.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Mab VTm1.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Shiga toxin 2</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>WP_115443648.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>562</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figures 2, 5 and 6</LocationOfData>
                        <BCellId>9995</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>WP_115443648.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>562</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Shiga 2 toxoid</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody was produced by hybridoma cell line obtained from the fusion of P3U1 mouse myeloma cells (5x3 10&lt;sup&gt;6&lt;/sup&gt; cells) with spleen cells from BALB/c mice immunized with Stx2 toxoid.  Toxoid used for immunizations was produced by formaldehyde treatment ofpurified Stx2.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The neutralization of Stx2 by the epitope-specific mAb was shown to be a result of the inhibition of Stx2 binding to its cellular receptor.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Mab VTm1.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Shiga toxin 2</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>WP_115443648.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>562</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

